Different Effects of Cigarette Smoke, Heated Tobacco Product and E-Cigarette Vapour on Orbital Fibroblasts in Graves' Orbitopathy; a Study by Real Time Cell Electronic Sensing

Molecules. 2022 May 7;27(9):3001. doi: 10.3390/molecules27093001.

Abstract

Thyroid autoimmunity in Graves’ disease (GD) is accompanied by Graves’ orbitopathy (GO) in 40% of the cases. Orbital fibroblasts (OF) play a key role in the pathogenesis and cigarette smoking is a known deteriorating factor. Alongside conventional cigarettes (CC) new alternatives became available for smokers, including heated tobacco products (HTP) and E-cigarettes (ECIG). We aimed to study the cellular effects of smoke extracts (SE) in orbital fibroblasts. Primary OF cultures from GO and NON-GO orbits were exposed to different concentrations of SE (1%, 50%) and the changes were followed using Real Time Cell Electronic Sensing (RT-CES). Untreated GO and NON-GO cells had different maximum cell index (CI) values of 3.3 and 2.79 respectively (p < 0.0001). CC, HTP and ECIG treated NON-GO fibroblasts exhibited peak CIs of 2.62, 3.32 and 3.41 while treated GO cells’ CIs were higher, 5.38, 6.25 and 6.33, respectively (p < 0.0001). The metabolic activity (MTT) decreased (p < 0.001) and hyaluronan production doubled (p < 0.02) after 50% of CC SE treatment in all cell cultures. GO fibroblasts were more sensitive to low concentration SE then NON-GO fibroblasts (p < 0.0001). The studied SEs exerted different effects. RT-CES is a sensitive technique to detect the effects of very low concentration of SE on fibroblasts.

Keywords: Graves orbitopathy (GO); alternative tobacco products; cigarette smoke extract; real time cell electronic sensing (RT CES); retrobulbar fibroblast.

MeSH terms

  • Cells, Cultured
  • Cigarette Smoking* / adverse effects
  • E-Cigarette Vapor*
  • Electronic Nicotine Delivery Systems*
  • Electronics
  • Fibroblasts
  • Graves Ophthalmopathy* / complications
  • Graves Ophthalmopathy* / metabolism
  • Graves Ophthalmopathy* / pathology
  • Humans
  • Tobacco Products*

Substances

  • E-Cigarette Vapor

Grants and funding

Research was supported by GINOP-2.3.4-15-2016-00002 and project no. TKP2021-EGA-18 416 has been implemented with the support provided from the National Research, Development and 417 Innovation Fund of Hungary, financed under the TKP2021-EGA funding scheme.